In Vitro: Tafluprost (3 μM, 48 h) decreases the number of apoptosis in RGC-5 cells. Tafluprost (0.1-100 μM, 48 h) enhances cell viability in RGC-5 cells in a dose-dependent manner.
In Vivo: Tafluprost (0.0015% AFP168 eye drops, continuous administration for 14 days) in male Sprague-Dawley rats can reduce optic nerve compression (ONC) intraocular pressure, increase RGC cell viability, and reduce retinal nerve cell apoptosis.